Dr. Anna Berkenblit, M.D., M.M.S., brings to Surrozen’s board more than 15 years of experience in clinical development, particularly of novel anticancer therapies in the life science industry. She is Chief Medical Officer at ImmunoGen where she is responsible for leading the clinical development of ImmunoGen’s novel, wholly owned product candidates. Prior to joining ImmunoGen, Dr. Berkenblit was Senior Vice President, Clinical Development at H3 Biomedicine, a developer of targeted anticancer compounds founded by Eisai Pharmaceuticals. Prior, she was Vice President, Head of Clinical Research at AVEO Oncology, where she led the clinical development of oncology product candidates spanning early testing to registration trials. Dr. Berkenblit held positions of increasing responsibility at Wyeth and then Pfizer, becoming Vice President, Neratinib Asset Team Leader in the Pfizer Oncology Business Unit. She earned an M.D. degree from Harvard Medical School, and an M.M.S. degree in the Clinical Investigator Training Program of Harvard/MIT Health Sciences & Technology. Dr. Berkenblit completed her internship and residency at Brigham and Women’s Hospital, then went on to a hematology/oncology fellowship at Beth Israel Deaconess Medical Center where she stayed on staff to focus on clinical research in GYN and GI malignancies. She also led the Phase I oncology clinical trial program as part of the Dana-Farber/Harvard Cancer Center, prior to transitioning to industry.